Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941389 · ClinicalTrials.gov registry record
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
A clinical trial of Sickle Cell Disease (SCD), sponsored by University of Rochester.
- Recruiting
- Registry status
- 480
- Enrollment target
- 20
- Study locations
NCT06941389 is a study of Sickle Cell Disease (SCD) that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 480 participants, above the 295-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06941389, a study of Sickle Cell Disease (SCD), is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD HCT group and 320 in the NT-DMT group, aged 3-20.9 years, the study will follow participants for three years, examining factors like disease severity, treatment history, and social determinants of health. By providing a comprehensive comparison, the study seeks to inform clinical decisions and improve understanding of SCD treatment outcomes, ultimately supporting families and healthcare providers in choosing the best treatment options.
Conditions Studied
Study Locations (20)
New York
- Roswell Park (MRD-HCT) - Buffalo
- Columbia Presbytarian (NT-DMT) - New York
- Cohen's Children Hospital (NT-DMT) - Queens
- University of Rochester (MRD-HCT) - Rochester
- University of Rochester (NT-DMT) - Rochester
- Children's Hospital at Montefiore (MRD HCT) - The Bronx
- Children's Hospital at Montefiore (NT-DMT) - The Bronx
Alabama
- Children's of Alabama (MRD-HCT) - Birmingham
- Children's of Alabama (NT-DMT) - Birmingham
Indiana
- Riley Children's Hospital (MRD-HCT) - Indianapolis
- Riley's Children Hospital (NT-DMT) - Indianapolis
Massachusetts
- Boston Children's Hospital (MRD-HCT) - Boston
- Boston Children's Hospital (NT-DMT) - Boston
Missouri
- Wahington Univ in St Louis (NT-DMT) - St Louis
- Washington University in St Louis (MRD-HCT) - St Louis
Delaware
- Nemours Children's Hospital, Delaware (MRD-HCT) - Wilmington
District of Columbia
- Children's National Hospital (MRD-HCT) - Washington D.C.
Georgia
- Children's Healthcare of Atlanta (MRD-HCT) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2030-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941389
The ClinicalTrials.gov registry entry for NCT06941389 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 295-participant average among 4 other Sickle Cell Disease (SCD) trials with a reported enrollment target (63% higher). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease (SCD) appearing as the primary indexed condition, and to 0 interventions.
NCT06941389 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, Alabama, Indiana.
Frequently Asked Questions
What is clinical trial NCT06941389 about?
NCT06941389 is a clinical study titled "Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease". The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-...
What is the current status of trial NCT06941389?
This trial is currently recruiting. The enrollment target is 480 participants. The study started on 2024-06-01. Estimated completion is 2030-10-01.
What conditions does trial NCT06941389 study?
This clinical trial studies the following conditions: Sickle Cell Disease (SCD).
Who is sponsoring clinical trial NCT06941389?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941389 being conducted?
This trial has 20 study locations across Alabama, Delaware, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease (SCD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sickle Cell Kidney Biorepository
RECRUITING
-
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
RECRUITING · Phase 4
-
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
ACTIVE NOT RECRUITING · Phase 3
-
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.